BOLT
Bolt Biotherapeutics, Inc. NASDAQ Listed Feb 5, 2021$4.28
+1.90%
vs $4.20
Mkt Cap $8.0M
52w Low $3.91
11.6% of range
52w High $7.09
50d MA $4.73
200d MA $5.12
P/E (TTM)
—
EV/EBITDA
—
P/B
0.3x
Debt/Equity
0.9x
ROE
-125.9%
P/FCF
-0.2x
RSI (14)
43.10
ATR (14)
$0.34
Beta
0.86
50d MA
$4.73
200d MA
$5.12
Avg Volume
31.5K
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
CIK (SEC)
Phone
650 665 9295
900 Chesapeake Drive · Redwood City, CA 94063 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -4.30 | -3.84 | +10.7% | 4.05 | -0.7% | -3.5% | +16.1% | -2.2% | +4.5% | -2.2% | — |
| Nov 12, 2025 | AMC | -5.07 | -3.72 | +26.6% | 4.69 | +8.5% | +0.2% | -2.8% | -1.3% | +2.4% | +1.3% | — |
| Aug 14, 2025 | AMC | -6.40 | -4.46 | +30.3% | 5.44 | -4.2% | -5.3% | -1.6% | -5.7% | +2.1% | +0.2% | — |
| May 12, 2025 | AMC | -6.80 | -5.80 | +14.7% | 7.40 | -2.7% | -6.8% | +1.4% | -9.4% | -7.6% | +11.8% | — |
| Mar 24, 2025 | AMC | -7.60 | -7.60 | +0.0% | 8.75 | -3.0% | -4.0% | +4.8% | -0.1% | -3.3% | -5.9% | — |
| Nov 12, 2024 | AMC | -0.36 | -0.40 | -11.1% | 12.84 | -1.9% | -3.9% | +0.9% | -9.2% | -1.1% | +0.4% | — |
| Aug 13, 2024 | AMC | -0.54 | -0.56 | -3.7% | 14.00 | -0.4% | -1.4% | +0.1% | +0.4% | -0.4% | -0.2% | — |
| May 14, 2024 | AMC | -0.51 | -0.28 | +45.1% | 26.40 | -22.7% | -37.1% | -0.6% | -3.9% | -0.4% | -1.9% | — |
| Mar 21, 2024 | AMC | -0.47 | -0.47 | +0.0% | 23.20 | +0.0% | +3.4% | +0.0% | -0.8% | +2.5% | +14.8% | — |
| Nov 9, 2023 | AMC | -0.49 | -0.43 | +12.2% | 19.60 | +0.0% | -1.0% | +1.0% | +0.0% | +0.0% | -3.1% | — |
| Aug 7, 2023 | AMC | -0.53 | -0.48 | +9.4% | 25.80 | +0.8% | +0.8% | -1.5% | +0.0% | -1.6% | -1.6% | — |
| May 11, 2023 | AMC | -0.49 | -0.45 | +8.2% | 32.00 | +8.8% | +12.5% | +8.3% | -5.1% | -2.7% | +5.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 29 | Rodman & Renshaw | Initiates | Buy | $22 | $5.30 | $5.49 | +3.6% | -0.9% | +1.1% | -3.8% | -9.4% | +2.8% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.05 | $4.02 | -0.7% | -3.5% | +16.1% | -2.2% | +4.5% | -2.2% |
| Aug 15 | Lake Street | Maintains | Buy → Buy | — | $5.44 | $5.21 | -4.2% | -5.3% | -1.6% | -5.7% | +2.1% | +0.2% |
| May 13 | Stifel | Maintains | Hold → Hold | — | $7.40 | $7.20 | -2.7% | -6.8% | +1.4% | -9.4% | -7.6% | +11.8% |
| Mar 25 | Stifel | Maintains | Hold → Hold | — | $8.75 | $8.49 | -3.0% | -4.0% | +4.8% | -0.1% | -3.3% | -5.9% |
| Mar 25 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $8.75 | $8.49 | -3.0% | -4.0% | +4.8% | -0.1% | -3.3% | -5.9% |
| May 15 | Stifel | Downgrade | Buy → Hold | — | $26.40 | $20.40 | -22.7% | -37.1% | -0.6% | -3.9% | -0.4% | -1.9% |
| May 15 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $26.40 | $20.40 | -22.7% | -37.1% | -0.6% | -3.9% | -0.4% | -1.9% |
| May 15 | Jones Trading | Downgrade | Buy → Hold | — | $26.40 | $20.40 | -22.7% | -37.1% | -0.6% | -3.9% | -0.4% | -1.9% |
| May 15 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $26.40 | $20.40 | -22.7% | -37.1% | -0.6% | -3.9% | -0.4% | -1.9% |
| May 15 | Guggenheim | Downgrade | Buy → Neutral | — | $26.40 | $20.40 | -22.7% | -37.1% | -0.6% | -3.9% | -0.4% | -1.9% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.20 | $23.20 | +0.0% | +3.4% | +0.0% | -0.8% | +2.5% | +14.8% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.80 | $26.00 | +0.8% | +0.8% | -1.5% | +0.0% | -1.6% | -1.6% |
| Jun 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.00 | $35.40 | +4.1% | -1.2% | -3.6% | -2.5% | +5.1% | -1.2% |
| May 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.00 | $37.20 | +0.5% | -1.1% | -6.6% | +0.6% | -1.2% | +0.0% |
| May 12 | SVB Leerink | Upgrade | Market Perform → Outperform | — | $32.00 | $34.80 | +8.8% | +12.5% | +8.3% | -5.1% | -2.7% | +5.6% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.00 | $34.80 | +8.8% | +12.5% | +8.3% | -5.1% | -2.7% | +5.6% |
| Mar 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.80 | $27.20 | +5.4% | +3.9% | +3.7% | +2.9% | -1.4% | -5.7% |
| Jan 24 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $30.60 | $31.00 | +1.3% | +0.7% | -3.2% | -2.0% | +0.7% | -4.1% |
| Oct 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.20 | $32.60 | +7.9% | +0.0% | -2.0% | +1.4% | -2.0% | -0.7% |
| Aug 11 | SVB Leerink | Downgrade | Outperform → Market Perform | — | $50.40 | $48.40 | -4.0% | -6.3% | -3.8% | -2.6% | -3.2% | -5.1% |
| May 17 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $31.00 | $31.40 | +1.3% | +13.5% | -10.8% | +5.7% | -1.8% | -4.3% |
| Jan 6 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $84.00 | $80.60 | -4.0% | -11.0% | +1.1% | -1.1% | +2.1% | -2.4% |
| Nov 10 | SVB Leerink | Maintains | Outperform → Outperform | — | $217.00 | $216.00 | -0.5% | -4.8% | -0.2% | +1.6% | -5.0% | -3.0% |
| Aug 16 | SVB Leerink | Maintains | Outperform → Outperform | — | $257.80 | $257.60 | -0.1% | -1.6% | +1.0% | +2.6% | -2.7% | +7.3% |
| May 17 | SVB Leerink | Maintains | Outperform → Outperform | — | $375.80 | $375.40 | -0.1% | -1.2% | +2.9% | -2.0% | +0.2% | +0.0% |
| Apr 6 | SVB Leerink | Maintains | Outperform → Outperform | — | $603.40 | $599.00 | -0.7% | -7.1% | -10.9% | -5.3% | -2.0% | -5.8% |
| Mar 2 | Stifel | Maintains | Buy → Buy | — | $600.00 | $660.00 | +10.0% | +5.5% | +1.6% | -10.5% | +4.3% | +5.3% |
| Mar 2 | SVB Leerink | Maintains | Outperform → Outperform | — | $600.00 | $660.00 | +10.0% | +5.5% | +1.6% | -10.5% | +4.3% | +5.3% |
| Mar 2 | Morgan Stanley | Maintains | Overweight → Overweight | — | $600.00 | $660.00 | +10.0% | +5.5% | +1.6% | -10.5% | +4.3% | +5.3% |
No insider trades available.
Institutional (13F) — Top 13
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Renaissance Technologies Llc | 77,225 | $312K | Added | Mar 2026 |
| 2 | Vivo Capital, Llc | 72,414 | $293K | New | Mar 2026 |
| 3 | Pfizer Inc | 31,305 | $137K | — | Mar 2026 |
| 4 | Nan Fung Group Holdings Ltd | 29,250 | $118K | Reduced | Mar 2026 |
| 5 | Nano Cap New Millennium Growth Fund L P | 20,500 | $112K | New | Dec 2025 |
| 6 | Susquehanna International Group, Llp | 11,657 | $47K | New | Mar 2026 |
| 7 | Citadel Advisors Llc | 10,109 | $41K | New | Mar 2026 |
| 8 | Morgan Stanley | 6,256 | $34K | — | Dec 2025 |
| 9 | Vanguard Capital Management Llc | 7,060 | $29K | New | Mar 2026 |
| 10 | Ubs Group Ag | 787 | $3K | Added | Mar 2026 |
| 11 | Citigroup Inc | 256 | $1K | New | Dec 2025 |
| 12 | Jpmorgan Chase & Co | 42 | $179 | — | Mar 2026 |
| 13 | Barclays Plc | 6 | $24 | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 5
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 8,636 | $39K | Feb 2026 |
| 2 | Fidelity Total Market Index Fund | 5,348 | $24K | Feb 2026 |
| 3 | Fidelity Series Total Market Index Fund | 1,699 | $8K | Feb 2026 |
| 4 | Fidelity Nasdaq Composite Index Fund | 143 | $646 | Feb 2026 |
| 5 | Guggenheim Active Allocation Fund | 6 | $27 | Feb 2026 |
Valuation
Market Cap
$8.0M
Enterprise Value
-$19.5M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.00x
P/B
0.30x
P/S
1.23x
P/FCF
-0.20x
EV/EBITDA
—
Shares Out
1.9M
Financials (TTM)
Revenue
$6.5M
Net Income
-$29.6M
EBITDA
-$28.5M
Free Cash Flow
-$39.9M
Op Cash Flow
-$39.9M
EPS Basic
$-17.85
EPS Diluted
$-15.89
EPS Forward
$-21.92
Gross Margin
96.9%
Op Margin
-463.4%
Net Margin
-455.1%
Balance Sheet
Total Assets
$56.7M
Total Liab.
$30.2M
Total Equity
$26.5M
Cash
$27.5M
LT Debt
$0
Book Value/Sh
$14.17
Debt/Equity
0.87x
Current Ratio
3.59
Quick Ratio
3.59
Returns & Growth
ROE
-125.9%
ROA
-58.8%
ROIC
-67.7%
Rev Growth YoY
+0.1%
EPS Growth YoY
-981.8%
Price Returns
2W
+5.0%
1M
+9.4%
3M
+16.2%
6M
+3.6%
12M
-16.5%
Technicals
52W High
$7.09
52W Low
$3.91
50d MA
$4.73
200d MA
$5.12
RSI (14)
43.10
ATR (14)
$0.34
Beta
0.86
Avg Volume
31K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$4.00
High
$7.00
Low
$1.00
Median
$4.00
Data updated apr 24, 2026 10:29pm
· Source: financialmodelingprep.com